@naultjc.bsky.social
Outcomes were strikingly distinct:
🔹 A had best OS (median not reached), lowest progression (25%), longest PFS (~11 mo).
🔸 B OS ~18 mo
🔸 C OS ~14 mo
Patterns held across BCLC stages + early hepatic decompensation risk.
🔹 A had best OS (median not reached), lowest progression (25%), longest PFS (~11 mo).
🔸 B OS ~18 mo
🔸 C OS ~14 mo
Patterns held across BCLC stages + early hepatic decompensation risk.
November 27, 2025 at 7:45 AM
Outcomes were strikingly distinct:
🔹 A had best OS (median not reached), lowest progression (25%), longest PFS (~11 mo).
🔸 B OS ~18 mo
🔸 C OS ~14 mo
Patterns held across BCLC stages + early hepatic decompensation risk.
🔹 A had best OS (median not reached), lowest progression (25%), longest PFS (~11 mo).
🔸 B OS ~18 mo
🔸 C OS ~14 mo
Patterns held across BCLC stages + early hepatic decompensation risk.
Three clusters emerged:
🔹 A (47.5%) – older, higher BMI, good liver function, multiple small tumors.
🔹 B (11%) – VP1/2 PVI, more HBV, fewer metabolic features.
🔹 C (41.2%) – worse liver function, high AFP, VP3/4 PVI or large tumor burden.
🔹 A (47.5%) – older, higher BMI, good liver function, multiple small tumors.
🔹 B (11%) – VP1/2 PVI, more HBV, fewer metabolic features.
🔹 C (41.2%) – worse liver function, high AFP, VP3/4 PVI or large tumor burden.
November 27, 2025 at 7:45 AM
Three clusters emerged:
🔹 A (47.5%) – older, higher BMI, good liver function, multiple small tumors.
🔹 B (11%) – VP1/2 PVI, more HBV, fewer metabolic features.
🔹 C (41.2%) – worse liver function, high AFP, VP3/4 PVI or large tumor burden.
🔹 A (47.5%) – older, higher BMI, good liver function, multiple small tumors.
🔹 B (11%) – VP1/2 PVI, more HBV, fewer metabolic features.
🔹 C (41.2%) – worse liver function, high AFP, VP3/4 PVI or large tumor burden.
5) CALCA (the PCT gene) is strongly overexpressed in FLC and spatial transcriptomics localizes CALCA to tumor cells.
November 23, 2025 at 10:59 AM
5) CALCA (the PCT gene) is strongly overexpressed in FLC and spatial transcriptomics localizes CALCA to tumor cells.
4) In 4 FLC patients, PCT tracked RECIST response under systemic treatment: ↓ in partial response, ↑ in progression, ↔ in stable disease. A promising dynamic monitoring marker.
November 23, 2025 at 10:59 AM
4) In 4 FLC patients, PCT tracked RECIST response under systemic treatment: ↓ in partial response, ↑ in progression, ↔ in stable disease. A promising dynamic monitoring marker.
3) Serum PCT is markedly elevated in FLC vs HCC, CCA or cirrhosis, in both EU & US cohorts.
👉 83% high PCT in FLC vs 0 to 3% in HCC or CCA.
👉 83% high PCT in FLC vs 0 to 3% in HCC or CCA.
November 23, 2025 at 10:59 AM
3) Serum PCT is markedly elevated in FLC vs HCC, CCA or cirrhosis, in both EU & US cohorts.
👉 83% high PCT in FLC vs 0 to 3% in HCC or CCA.
👉 83% high PCT in FLC vs 0 to 3% in HCC or CCA.
Claudia Campani from Cordeliers Research Center received Best clinical poster award in @ILCAnews meeting in Hong Kong
November 20, 2025 at 4:13 AM
Claudia Campani from Cordeliers Research Center received Best clinical poster award in @ILCAnews meeting in Hong Kong
Claudia Campani presenting our work on Molecular based therapy in primary liver cancer refractory to systemic treatments in ILCA meeting in Hong Kong
November 20, 2025 at 3:56 AM
Claudia Campani presenting our work on Molecular based therapy in primary liver cancer refractory to systemic treatments in ILCA meeting in Hong Kong
Our work about « Molecular based targeted therapies in primary liver cancers » presented by Claudia Campani at ESMO precision medicine @myesmo.bsky.social
September 16, 2025 at 11:22 AM
Our work about « Molecular based targeted therapies in primary liver cancers » presented by Claudia Campani at ESMO precision medicine @myesmo.bsky.social
Iron Maiden, Paris 2025
July 20, 2025 at 9:30 AM
Iron Maiden, Paris 2025
Kendrick Lamar/SZA Paris 2025
July 17, 2025 at 6:31 PM
Kendrick Lamar/SZA Paris 2025
Neil Young, Paris 2025
July 13, 2025 at 9:08 PM
Neil Young, Paris 2025
Joe Satriani and Steve Vaï, Paris 2025
June 23, 2025 at 4:44 AM
Joe Satriani and Steve Vaï, Paris 2025
Pr Éric Trepo on genetic prédisposition to HCC on alcohol related liver Disease in the Paris Liver Cancer Group Day, June 2025
June 19, 2025 at 9:22 PM
Pr Éric Trepo on genetic prédisposition to HCC on alcohol related liver Disease in the Paris Liver Cancer Group Day, June 2025
Paris Liver Cancer Group day, 19 June 2025.
June 19, 2025 at 9:21 PM
Paris Liver Cancer Group day, 19 June 2025.
Paris Liver Cancer Group day, 19 June 2025.
June 19, 2025 at 9:19 PM
Paris Liver Cancer Group day, 19 June 2025.
4/
⚠️ Prognostic implications
Biopsy uncovered 3% cholangiocarcinoma/hepatocholangiocarcinoma—linked to significantly shorter survival.
Also, macrotrabecular-massive HCC subtype had higher recurrence (P=0.037).
⚠️ Prognostic implications
Biopsy uncovered 3% cholangiocarcinoma/hepatocholangiocarcinoma—linked to significantly shorter survival.
Also, macrotrabecular-massive HCC subtype had higher recurrence (P=0.037).
April 25, 2025 at 6:24 PM
4/
⚠️ Prognostic implications
Biopsy uncovered 3% cholangiocarcinoma/hepatocholangiocarcinoma—linked to significantly shorter survival.
Also, macrotrabecular-massive HCC subtype had higher recurrence (P=0.037).
⚠️ Prognostic implications
Biopsy uncovered 3% cholangiocarcinoma/hepatocholangiocarcinoma—linked to significantly shorter survival.
Also, macrotrabecular-massive HCC subtype had higher recurrence (P=0.037).
2/We looked in 248 patients at safety, diagnostic yield & prognostic insights from tumor + non-tumor biopsies.
✅ Safety first
Biopsies done during RFA had a low complication rate:
🔹 Bleeding in only 1.9% of cases
🔹 No biopsy-related deaths
✅ Safety first
Biopsies done during RFA had a low complication rate:
🔹 Bleeding in only 1.9% of cases
🔹 No biopsy-related deaths
April 25, 2025 at 6:24 PM
2/We looked in 248 patients at safety, diagnostic yield & prognostic insights from tumor + non-tumor biopsies.
✅ Safety first
Biopsies done during RFA had a low complication rate:
🔹 Bleeding in only 1.9% of cases
🔹 No biopsy-related deaths
✅ Safety first
Biopsies done during RFA had a low complication rate:
🔹 Bleeding in only 1.9% of cases
🔹 No biopsy-related deaths
Fire walk with him
January 16, 2025 at 8:03 PM
Fire walk with him